ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit

Rhea-AI Summary

ProMIS Neurosciences, a biotechnology company, will present at the 10th Annual Neurodegenerative Drug Development Summit in Boston from March 28-30, 2022. Chief Scientific Officer Dr. Neil Cashman will discuss targeting misfolded proteins, particularly amyloid beta oligomers related to Alzheimer’s disease, in his presentation titled “Abeta oligomers in Alzheimer Disease: Target Engagement and Target Distraction” on March 29 at 3 PM. The presentation focuses on a proprietary computational algorithm, Collective Coordinates, to design conformational epitopes for selective targeting. For details, visit ProMIS Neurosciences.

TORONTO, Ontario and CAMBRIDGE, MA , March 24, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it will be presenting at the upcoming 10^th Annual Neurodegenerative Drug Development Summit, to be held in Boston, MA, March 28-30, 2022.

ProMIS Chief Scientific Officer, Dr. Neil Cashman, will deliver an oral presentation entitled: “Abeta oligomers in Alzheimer Disease: Target Engagement and Target Distraction”, on Tuesday, March 29, 2022, at 3 PM local time at the Boston Park Plaza Hotel.

Much scientific data has implicated misfolded oligomers as the toxic molecular species of amyloid beta (Abeta) relevant to Alzheimer’s disease. However, using conventional methods, it has proven difficult to selectively target oligomers while sparing other species – including monomers and fibrils – which “distract” a therapeutic antibody from its primary target. Immune recognition of Abeta fibrils can also lead to dose-limiting adverse effects. In his presentation, Dr. Cashman will discuss the use of Collective Coordinates^TM, a proprietary computational algorithm, to design conformational epitopes that specifically target oligomers, while sparing monomers and fibrils from immune recognition.

Dr. Cashman’s presentation will be available on the ProMIS website (www.promisneurosciences.com) at the conclusion of the meeting. For more information about the meeting please consult the organizer’s website here.

About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing therapeutics selectively targeting toxic misfolded oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary computational modeling techniques. The Company applies its molecular dynamics, computational discovery platform -ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF

To learn more, visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

###

FAQ

What is ProMIS Neurosciences presenting at the Neurodegenerative Drug Development Summit?

ProMIS Neurosciences will present on targeting amyloid beta oligomers in Alzheimer’s disease, focusing on a presentation by Dr. Neil Cashman.

When is ProMIS Neurosciences' presentation at the summit?

The presentation is scheduled for March 29, 2022, at 3 PM local time.

What is the focus of Dr. Neil Cashman's presentation?

Dr. Cashman's presentation focuses on the challenges of targeting amyloid beta oligomers while avoiding other forms like monomers and fibrils.

How does ProMIS Neurosciences target misfolded proteins?

ProMIS uses a proprietary algorithm called Collective Coordinates to design conformational epitopes that selectively target toxic oligomers.

Where can I find more information about the Neurodegenerative Drug Development Summit?

More information can be found on the summit organizer's website and ProMIS Neurosciences' presentation will be available on their website post-meeting.